shutterstock_1425740486_ii_studio

II Studio / Shutterstock.com

24 October 2019Big PharmaSaman Javed

Brazil accuses Gilead over 1,421.5% price hike of hep C drug

The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

More on this story

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

More on this story

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility